In a report issued on July 25, Catherine Ramsey Schulte from Robert W. Baird maintained a Buy rating on Castle Biosciences (CSTL – Research Report), with a price target of $44.00. The company’s shares closed last Tuesday at $27.32.
According to TipRanks.com, Schulte is a 5-star analyst with an average return of 16.7% and a 57.8% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Twist Bioscience, NanoString Tech, and Mettler-Toledo.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $43.50 average price target, implying a 70.2% upside from current levels. In a report issued on July 14, SVB Securities also maintained a Buy rating on the stock with a $45.00 price target.
The company has a one-year high of $78.59 and a one-year low of $15.58. Currently, Castle Biosciences has an average volume of 359.3K.
Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CSTL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Read More on CSTL:
- SVB Securities Maintains a Buy Rating on Sanofi (SNYNF)
- Robert W. Baird Reaffirms Their Buy Rating on Wingstop (WING)
- Aurinia Pharmaceuticals (AUPH) Receives a Buy from SVB Securities
- SVB Securities Reaffirms Their Buy Rating on IQVIA Holdings (IQV)
- Mizuho Securities Keeps a Buy Rating on Tenet Healthcare (THC)